TNFerade + 5-fluorouracil

**TNFerade + 5-fluorouracil** is a combination regimen used primarily for the treatment of locally advanced pancreatic cancer. TNFerade Biologic (AdGVEGR.TNF.11D) is a replication-deficient adenoviral vector gene therapy designed to express human tumor necrosis factor-alpha (TNF-α) under the control of the Egr-1 promoter, which is activated by chemotherapy (such as 5-fluorouracil) and radiation. This gene therapy is administered directly into the tumor via endoscopic ultrasound (EUS) or percutaneous injection. The standard chemotherapy in this combination is **5-fluorouracil (5-FU)**, a classic antimetabolite cytotoxic agent that inhibits thymidylate synthase, blocking DNA synthesis and inducing apoptosis in rapidly dividing cells. The combination is typically administered alongside radiotherapy[1][2]. Trials have found this combination feasible and relatively safe, with the maximal tolerated dose for TNFerade Biologic defined as 4 × 10^11 particle units in combination with standard 5-FU and radiotherapy. TNFerade is developed by GenVec.

Brand names

TNFeradeBiologic5-FU

Other names

TNFeradeAdGVEGR.TNF.11D5-fluorouracil5-FU